Compounds > prednisone
Page last updated: 2024-11-07

prednisone and Impaired Glucose Tolerance

prednisone has been researched along with Impaired Glucose Tolerance in 7 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

ExcerptRelevanceReference
" The main adverse effects in TAC treatment were glucose intolerance, diabetes and abnormal aminotransferase."6.84The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. ( Chen, J; Li, H; Li, X; Liang, Q; Qu, F; Xie, X, 2017)
" This study assessed whether treatment with the glucagon-like peptide receptor agonist (GLP-1 RA) exenatide (EXE) could prevent GC-induced glucose intolerance."5.15Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. ( Diamant, M; Linssen, MM; Ouwens, DM; van Genugten, RE; van Raalte, DH, 2011)
" The main adverse effects in TAC treatment were glucose intolerance, diabetes and abnormal aminotransferase."2.84The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. ( Chen, J; Li, H; Li, X; Liang, Q; Qu, F; Xie, X, 2017)
"Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation."1.35Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961. ( Hawks, RG; Meza, JL; Post-White, JE; Sacks, N; Seibel, NL; Smith, LM; Withycombe, JS, 2009)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Machado, MPR1
Schavinski, AZ1
Deluque, AL1
Volpato, GT1
Campos, KE1
Liang, Q1
Li, H1
Xie, X1
Qu, F1
Li, X1
Chen, J1
Withycombe, JS1
Post-White, JE1
Meza, JL1
Hawks, RG1
Smith, LM1
Sacks, N1
Seibel, NL1
van Raalte, DH1
van Genugten, RE1
Linssen, MM1
Ouwens, DM1
Diamant, M1
Manrique, J1
Rossich, E1
Hernández Sierra, A1
Delgado, P1
Diaz, JM1
Silva, I1
Osorio, JM1
Osuna, A1
Bayés, B1
Lauzurica, R1
Arellano, E1
Campistol, JM1
Dominguez, R1
Gómez-Alamillo, C1
Ibernon, M1
Moreso, F1
Benitez, R1
Lampreave, I1
Porrini, E1
Torres, A1
Vondra, K1
Nĕmcová, D1
Stárka, L1
Bílek, R1
Bendlová, B1
Hampl, R1
Hill, M1
Hoza, J1
Kot'átková, A1
Vrbíková, J1
Zamrazil, V1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)[NCT03549663]108 participants (Anticipated)Interventional2018-07-04Recruiting
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study[NCT00002812]Phase 32,078 participants (Actual)Interventional1996-09-30Completed
Prednisolone-induced Impairment of Glucose Metabolism and Beta-cell Dysfunction and the Protective Effects of Exenatide: a Single-center, Randomized, Double-blind, Placebo-controlled Crossover Study in Healthy Volunteers[NCT00744224]8 participants (Anticipated)Interventional2009-02-28Completed
Optimum Immunosuppression in Renal Transplant Recipients at High Risk of Developing New Onset Diabetes After Transplantation: A Multicenter, Prospective, Controlled and Randomized Trial.[NCT01002339]Phase 4134 participants (Actual)Interventional2010-02-28Terminated (stopped due to Terminated: higher rate of acute rejection in the Cyclosporin A group)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Blood Pressure

Diastolic pressure (mmHg) (NCT01002339)
Timeframe: 1 year

InterventionmmHg (Mean)
Tacrolimus With Rapid Steroid Withdrawal76.67
Tacrolimus With Steroids Minimization74.59
CsA With Steroid Minimization76.64

Blood Pressure

Systolic pressure (mmHg) (NCT01002339)
Timeframe: 1 year

InterventionmmHg (Mean)
Tacrolimus With Rapid Steroid Withdrawal135.36
Tacrolimus With Steroids Minimization133.97
CsA With Steroid Minimization136.28

Changes of Carotid Intima-media Thickness Over Time

absolute difference between carotid intima-media thickness at study end versus baseline. (NCT01002339)
Timeframe: 1 year

Interventionmm (Mean)
Tacrolimus With Rapid Steroid Withdrawal0.12
Tacrolimus With Steroids Minimization0.04
CsA With Steroid Minimization0.01

Lipidic Profile (Cholesterol)

Lipidic Profile (total cholesterol) (NCT01002339)
Timeframe: 1 year

Interventionmg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal169.05
Tacrolimus With Steroids Minimization178.24
CsA With Steroid Minimization168.89

Lipidic Profile (HDL-c)

(NCT01002339)
Timeframe: 1 year

Interventionmg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal44.84
Tacrolimus With Steroids Minimization49.29
CsA With Steroid Minimization48.35

Lipidic Profile (LDL-c)

(NCT01002339)
Timeframe: 1 year

Interventionmg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal94.00
Tacrolimus With Steroids Minimization95.43
CsA With Steroid Minimization88.65

Lipidic Profile (Triglycerides)

(NCT01002339)
Timeframe: 1 year

Interventionmg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal159.44
Tacrolimus With Steroids Minimization145.59
CsA With Steroid Minimization160.78

Number of Antihypertensive Drugs Patients Reported Taking.

(NCT01002339)
Timeframe: 1 year

Interventionnumber of antihypertensive drugs (Median)
Tacrolimus With Rapid Steroid Withdrawal2
Tacrolimus With Steroids Minimization2
CsA With Steroid Minimization2

Patients Treated With Insulin or Oral Antidiabetic Drugs

(NCT01002339)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal20
Tacrolimus With Steroids Minimization15.4
CsA With Steroid Minimization2.6

Percentage of Patients Using Acetylsalicylic Acid (ASA)

(NCT01002339)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal53.9
Tacrolimus With Steroids Minimization48.7
CsA With Steroid Minimization52.8

Percentage of Patients Using Statins

(NCT01002339)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal56.
Tacrolimus With Steroids Minimization61.5
CsA With Steroid Minimization73.7

Primary Outcome Measure (Glucose Intolerance)

Glycemia >=140 and <200 mg/dl, 2 hours after a standard oral glucose tolerance test. Measured values: glucose intolerance at 1 year defined by ADA criteria. (NCT01002339)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal26.9
Tacrolimus With Steroids Minimization31.0
CsA With Steroid Minimization33.3

Proteinuria

(NCT01002339)
Timeframe: 1 year

Interventionmg/day (Mean)
Tacrolimus With Rapid Steroid Withdrawal208
Tacrolimus With Steroids Minimization241
CsA With Steroid Minimization343.2

Rejection

Biopsy proven acute rejection. Measured variable: Rate of Biopsy proven acute rejection. (NCT01002339)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal11.4
Tacrolimus With Steroids Minimization4.8
CsA With Steroid Minimization21.4

Renal Function

Estimated Glomerular Filtration Rate (ml/min/1.73 m^2) (NCT01002339)
Timeframe: 1 year

Interventionml/min/1.73 m^2 (Mean)
Tacrolimus With Rapid Steroid Withdrawal51.9
Tacrolimus With Steroids Minimization47.4
CsA With Steroid Minimization44.6

"Primary Outcome Measure New Onset Diabetes After Renal Transplantation (NODAT)"

American Diabetes Association criteria (ADA) including an oral glucose tolerance test. (NCT01002339)
Timeframe: 1 year

,,
Interventionpercentage of participants (Number)
% of patients with NODAT% of patients without NODAT
CsA With Steroid Minimization7.992.1
Tacrolimus With Rapid Steroid Withdrawal34.165.9
Tacrolimus With Steroids Minimization23.176.9

Trials

2 trials available for prednisone and Impaired Glucose Tolerance

ArticleYear
The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
    Renal failure, 2017, Volume: 39, Issue:1

    Topics: Adult; Cyclophosphamide; Diabetes Mellitus; Drug Therapy, Combination; Female; Glomerular Filtration

2017
Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.
    Diabetes care, 2011, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Blood Glucose; C-Peptide; Cross-Over Studies; Exenatide; Glucagon-Like Peptide 1;

2011

Other Studies

5 other studies available for prednisone and Impaired Glucose Tolerance

ArticleYear
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response.
    Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:5

    Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Glucocorticoids; Glucose Intol

2020
Weight patterns in children with higher risk ALL: A report from the Children's Oncology Group (COG) for CCG 1961.
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Body Mass Ind

2009
[Multiple complications after renal transplantation].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2004, Volume: 24 Suppl 3

    Topics: Adult; Azathioprine; Cataract; Cholecystitis; Choledocholithiasis; Cyclosporine; Femur Head Necrosis

2004
Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study.
    Clinical journal of the American Society of Nephrology : CJASN, 2008, Volume: 3, Issue:3

    Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Blood Glucose; Cross-Sectional Studies; Diabetes Me

2008
[Metformin has a positive effect on disorders of carbohydrate metabolism in long-term care with low doses of prednisone].
    Casopis lekaru ceskych, 2002, Apr-26, Volume: 141, Issue:8

    Topics: Adolescent; Adult; Female; Glucocorticoids; Glucose Intolerance; Glucose Tolerance Test; Humans; Hyp

2002